ArticleWiener medizinische Wochenschrift (1946)2026
Vitamin D and bone health in psoriatic arthritis: bone mineral density, turnover markers, and biochemical measures.
Article in Wiener medizinische Wochenschrift (1946), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriatic arthritis (PsA) is an autoimmune disease that often leads to joint inflammation and bone changes, including osteoporosis. The role of vitamin D in bone health is well documented, but its effects in PsA, particularly regarding bone mineral density (BMD), trabecular bone score (TBS), and bone turnover markers (BTM), remain unclear. This study aimed to evaluate the relationship between vitamin D status and these bone parameters in PsA patients. MATERIALS AND
methodsA cross-sectional study was conducted with 68 patients diagnosed with PsA. Participants were divided into two groups based on their 25(OH)D3 concentrations (< 75 nmol/L and > 75 nmol/L). Patients' BMD and TBS were measured using dual-energy X‑ray absorptiometry (DXA), while serum samples were analyzed for calcium, phosphorus, osteocalcin, CTX‑I, and parathyroid hormone (PTH) concentrations.
resultsPatients with 25(OH)D3 levels > 75 nmol/L showed significantly lower BMD at the lumbar spine compared to those with levels < 75 nmol/L (P = 0.020). Significant differences were observed in BTM, with higher concentrations of osteocalcin and CTX‑I in patients with 25(OH)D3 levels > 75 nmol/L. No significant differences were found for TBS, alkaline phosphatase, or other biochemical parameters.
conclusionOur findings indicate potential differences in lumbar spine BMD and bone turnover markers across vitamin D levels in PsA patients. The findings highlight the complexity of bone metabolism in PsA and suggest that vitamin D supplementation may have a nuanced impact on bone health. Further studies with larger cohorts are needed to confirm these results and explore their clinical implications.
Indexed as
Identifiers
42789164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.